Skip to main content
Top
Published in: European Radiology 8/2020

01-08-2020 | Magnetic Resonance Imaging | Breast

Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area

Authors: Federica Rossi, Lorenzo Torri, Matteo Lambertini, Sara De Giorgis, Massimo Calabrese, Alberto Stefano Tagliafico

Published in: European Radiology | Issue 8/2020

Login to get access

Abstract

Objectives

The loss of skeletal muscle mass is widely considered a predictor of poor survival and toxicity in breast cancer patients. The aim of this study is to evaluate if there is pectoralis muscle area (PMA) variation, reflecting loss of skeletal muscle mass, on consecutive MRI examinations after neoadjuvant chemotherapy.

Methods

The retrospective study protocol was approved by our institutional review board. A total of n = 110 consecutive patients (mean age 56 ± 11 years) who were treated with neoadjuvant chemotherapy (NAC) for histologically proven primary breast cancer between January 2017 and January 2019 and in whom tumor response was checked with standard breast MRI were included. Two radiologists calculated the pectoralis muscle cross-sectional area before and after NAC.

Results

Time between the MRI examinations, before starting NAC and after completing NAC, was 166.8 ± 50 days. PMA calculated pre-NAC (8.14 cm2) was larger than PMA calculated post-NAC (7.03 cm2) (p < 0.001). According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, there were no significant differences between responders (complete or partial response) and non-responders (p = 0.362). The multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI exams, estrogen and progesterone receptor status, human epidermal growth factor receptor status (HER-2), Ki-67 expression, lymph node status, RECIST criteria, histological type, average lesion size, molecular categories, and grade. Inter-reader (k = 0.72) and intra-reader agreement (0.69 and 0.71) in PMA assessment were good.

Conclusions

Pectoralis muscle mass varies in breast cancer patients undergoing NAC and this difference can be estimated directly on standard breast MRI.

Key Points

• Pectoralis muscle area variation reflects loss of skeletal muscle mass.
• Pectoralis muscle area on MRI is reduced after NAC.
• Pectoralis muscle mass loss seems independent from other variables.
Literature
1.
go back to reference Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804CrossRef Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804CrossRef
2.
go back to reference Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861–868CrossRef Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861–868CrossRef
3.
go back to reference Klassen O, Schmidt ME, Ulrich CM et al (2017) Muscle strength in breast cancer patients receiving different treatment regimes. J Cachexia Sarcopenia Muscle 8:305–316CrossRef Klassen O, Schmidt ME, Ulrich CM et al (2017) Muscle strength in breast cancer patients receiving different treatment regimes. J Cachexia Sarcopenia Muscle 8:305–316CrossRef
4.
go back to reference Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6:398–406CrossRef Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6:398–406CrossRef
5.
go back to reference Mazzuca F, Onesti CE, Roberto M et al (2018) Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget 9:25714–25722CrossRef Mazzuca F, Onesti CE, Roberto M et al (2018) Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget 9:25714–25722CrossRef
6.
go back to reference Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516CrossRef Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516CrossRef
7.
go back to reference Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316CrossRef Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316CrossRef
8.
go back to reference Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678CrossRef Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678CrossRef
9.
go back to reference Rossi F, Valdora F, Barabino E, Calabrese M, Tagliafico AS (2019) Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI. Eur Radiol 29:494–500CrossRef Rossi F, Valdora F, Barabino E, Calabrese M, Tagliafico AS (2019) Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI. Eur Radiol 29:494–500CrossRef
10.
go back to reference Rossi F, Valdora F, Bignotti B, Torri L, Succio G, Tagliafico AS (2019) Evaluation of body computed tomography-determined sarcopenia in breast cancer patients and clinical outcomes: a systematic review. Cancer Treat Res Commun 21:100154CrossRef Rossi F, Valdora F, Bignotti B, Torri L, Succio G, Tagliafico AS (2019) Evaluation of body computed tomography-determined sarcopenia in breast cancer patients and clinical outcomes: a systematic review. Cancer Treat Res Commun 21:100154CrossRef
11.
go back to reference Seo A, Hwang JM, Lee JM, Jung TD (2019) Changes in pectoral muscle volume during subacute period after radiation therapy for breast cancer: a retrospective up to 4-year follow-up study. Sci Rep 9:7038CrossRef Seo A, Hwang JM, Lee JM, Jung TD (2019) Changes in pectoral muscle volume during subacute period after radiation therapy for breast cancer: a retrospective up to 4-year follow-up study. Sci Rep 9:7038CrossRef
12.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRef Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRef
13.
go back to reference Londero V, Bazzocchi M, Del Frate C et al (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371–1379CrossRef Londero V, Bazzocchi M, Del Frate C et al (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371–1379CrossRef
14.
go back to reference Del Fabbro E, Parsons H, Warneke CL et al (2012) The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240–1245CrossRef Del Fabbro E, Parsons H, Warneke CL et al (2012) The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240–1245CrossRef
15.
go back to reference Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95–105CrossRef Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95–105CrossRef
16.
go back to reference Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRef Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRef
17.
go back to reference Iwase T, Sangai T, Nagashima T et al (2016) Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 5:41–48CrossRef Iwase T, Sangai T, Nagashima T et al (2016) Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 5:41–48CrossRef
18.
go back to reference Strigel RM, Rollenhagen J, Burnside ES et al (2017) Screening breast MRI outcomes in routine clinical practice: comparison to BI-RADS benchmarks. Acad Radiol 24:411–417CrossRef Strigel RM, Rollenhagen J, Burnside ES et al (2017) Screening breast MRI outcomes in routine clinical practice: comparison to BI-RADS benchmarks. Acad Radiol 24:411–417CrossRef
19.
go back to reference Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRef
20.
go back to reference Saini A, Faulkner S, Al-Shanti N, Stewart C (2009) Powerful signals for weak muscles. Ageing Res Rev 8:251–267CrossRef Saini A, Faulkner S, Al-Shanti N, Stewart C (2009) Powerful signals for weak muscles. Ageing Res Rev 8:251–267CrossRef
Metadata
Title
Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area
Authors
Federica Rossi
Lorenzo Torri
Matteo Lambertini
Sara De Giorgis
Massimo Calabrese
Alberto Stefano Tagliafico
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 8/2020
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06799-5

Other articles of this Issue 8/2020

European Radiology 8/2020 Go to the issue